Inflarx NV (IFRX) Given Average Rating of “Buy” by Brokerages

Shares of Inflarx NV (NASDAQ:IFRX) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $42.67.

IFRX has been the topic of a number of recent research reports. SunTrust Banks initiated coverage on Inflarx in a research report on Thursday, June 28th. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Investment Research raised Inflarx from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. Raymond James initiated coverage on Inflarx in a research report on Thursday, June 28th. They issued an “outperform” rating and a $44.00 target price on the stock. Finally, BMO Capital Markets initiated coverage on Inflarx in a research report on Friday, July 13th. They issued an “outperform” rating and a $45.00 target price on the stock.

Shares of Inflarx stock opened at $34.32 on Friday. Inflarx has a 52-week low of $14.47 and a 52-week high of $42.83. The company has a market capitalization of $813.15 million and a P/E ratio of -11.67.

Inflarx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.24. equities analysts expect that Inflarx will post -1.43 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in IFRX. Barclays PLC acquired a new position in shares of Inflarx during the 1st quarter worth approximately $144,000. Northern Trust Corp acquired a new position in shares of Inflarx during the 1st quarter worth approximately $228,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Inflarx during the 1st quarter worth approximately $367,000. Birchview Capital LP acquired a new position in shares of Inflarx during the 2nd quarter worth approximately $516,000. Finally, Millennium Management LLC acquired a new position in shares of Inflarx during the 2nd quarter worth approximately $1,916,000. 54.80% of the stock is currently owned by institutional investors and hedge funds.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Story: Google Finance Portfolio

Analyst Recommendations for Inflarx (NASDAQ:IFRX)



Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Here is a look at the possible causes behind armpit lumps?

The appearance of painful lumps which are usually referred to as boils or lumps can be irritating especially when they occur on the armpit. Armpit lump can appear due to bacterial growth or growth in the lymph nodes. Lymph nodes are basically small glands that are present throughout the body and are responsible for maintaining the body’s balance. Apart from lymph nodes, an infection and cyst growth can also cause lumps.

Here is a look at the probable causes behind armpit lumps:

  1.    Lack of hygiene

Armpits are sensitive areas on the body. Excessive sweating in this area makes it vulnerable and exposes it to bacteria and other germs. Painful lumps usually appear when sweat and germs get trapped in the hair follicle. The odds of this happening multiple when the armpits are not washed regularly. This is the reason that hygiene plays a great part in your health.

  1.    Hidradenitis suppurativa

Hidradenitis suppurativa is an infectious condition, which results in extreme inflammation and irritation. As armpit is the area where there is moisture and smell due to sweating, therefore, during this infection fluid with odor is trapped in the lumps, which culminates in scarring.

  1.    Allergic reactions

Sometimes the appearance of lumps is a sign of a reaction to either a vaccination shot or any other medicine. These lumps occur as the inflammation caused in the lymph nodes swell. Usually, this condition is not much troublesome. However, if the lumps stay for a relatively long time or become extremely painful then contact your doctor as soon as possible.

  1.    Ingrown hair

No one likes excessive hair growth and you may remove them as soon as their head pops up. However, removing hair through shaving continuously may cause the hair to grow inside. The ingrowth of hair results in a painful lump and then at time pus start filling up these lumps. Contact your physician when you see these lumps growing.

  1.    Skin abscess

Lumps caused by skin abscess are the result of an infection. These lumps usually occur deep into the skin and show red bumps that are more like blisters. Staph bacteria can be usually blamed as the culprit for a skin abscess. You should rush to your doctor for an antibacterial treatment and other skin care measures.

  1.    Lipoma

Lipoma is a soft and mushy bump that surfaces when fat is accumulated under the skin. This lump is relatively harmless and is quite small. It can even be felt moving under the touch of your skin. Though lipoma is not harmful, if it starts causing painful symptoms, then you should consult your doctor as the lipoma may be hurting any nearby nerves. There are natural remedies as well as a surgical method of removing it.

  1.    Skin cyst

Cyst caused under the skin is also a condition, which results in the formation of lumps. A skin cyst is basically sacs formed inside the skin and accumulate oily fluids. Such boils usually appear after an injury or any accident that may hurt the skin or they may appear after a surgery. These are usually skin colored and appear in small sizes. You can consult your doctor but they may vanish themselves.

  1.    Viruses

Lastly, lumps under the arm may also be the result of any virus that may have infected measles, chickenpox and HIV infection. These are few of the infectious situation that can result in painful lumps. All these three conditions demand medical attention. Proper treatment is available to cure them.

Where, at times, these lumps may not be so harmful, they can be an alarming sign. This is particularly true if the lumps occur in places that are sensitive. Hence,  it is best to get in touch with a doctor.

Source link

XBiotech (XBIT) Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases


Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.


XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization programs.

Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, “I am pleased that the European Patent Office acknowledged the significance of XBiotech’s contribution to this field by granting this patent with broad claims. As a pioneer in IL-1α research, XBiotech has developed a significant worldwide patent portfolio for the use of bermekimab to prevent and treat inflammatory skin diseases as well as other conditions involving sterile inflammation.”

This patent issuance further broadens XBiotech’s patent portfolio as it relates to bermekimab and its potential to treat inflammatory skin disorders through IL-1α blockade. XBiotech previously conducted clinical studies with bermekimab to treat dermatological conditions including psoriasis1, acne2 and hidradenitis suppurativa3. The Company is currently conducting two separate open label, phase 2, multi-center studies evaluating a subcutaneous formulation of bermekimab in pre-filled syringes for treatment of atopic dermatitis and hidradenitis suppurativa.

The grant of this patent in Europe is in addition to patents granted in the US, Australia, and Japan. The Company’s patent portfolio also includes several pending U.S. and foreign applications directed to dermatologic pathologies. The Company plans to continue to pursue inflammatory skin disorder indications as it further strengthens its clinical pipeline.

About 85 million Americans sought treatment from a physician for skin disease in 2013, with an estimated direct health care cost of $75 billion4. The economic impact and prevalence of skin disease is on a similar magnitude as other major diseases affecting the US population, including diabetes and cardiovascular disease. Consequently, revenues from new biological drugs used to treat skin diseases are growing rapidly. XBiotech believes bermekimab may emerge as a major new therapy for skin disease.

Dr. Kim has been XBiotech’s chief intellectual property counsel for over 10 years. Prior to joining XBiotech, Dr. Kim led his law firm’s patent and life sciences practices. Dr. Kim is a registered patent attorney, experienced in procuring domestic and foreign patents, licensing and joint ventures, intellectual property opinions and due diligence, strategic patent portfolio development, and intellectual property litigation matters. Dr. Kim holds a bachelor’s degree in Biology from Bowdoin College, a Ph.D. in Microbiology and Immunology from the University of Miami, and a law degree from Suffolk University.

Source link

XBiotech announces granting of European patent for treatment of inflammatory skin diseases

… studies evaluating a subcutaneous formulation of bermekimab in pre-filled syringes for treatment of atopic dermatitis and hidradenitis suppurativa.

Source link

FDA to review Samsung Bioepis' application for anti-arthritis biosimilar

… pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, and uveitis.

Source link

Stephanie Hill: On parenting young adults and thanking those helpers who listen | Features/Entertainment

“Be careful what you wish for, you may receive it.” — W.W. Jacobs.

“One of the greatest gifts I have ever gotten is my daughter.” — Ace Frehley.

Warning to the reader: The following words are full of the heart, sentimentality, and the emotion of a parent. While I originally planned to write part two of a travel piece, it will have to wait as I must, instead, write from a deep sense of gratitude. If sappy stories don’t appeal to you, then perhaps this piece of writing is not for you.

Friday mornings at my school, St. Joseph Catholic School, are devoted to church. Our weekly church service for students, staff and community is a part of our schedule to which I look forward. I love seeing students of all faith backgrounds, grades kindergarten through eight, come together for the sole purpose of quieting the heart and mind in order to hear God speak.

This past Friday was no exception. For whatever reason, my homeroom students and I were the first to arrive for Mass. As we made our way to the designated pews, we all knelt together. I was struck by a gnawing feeling I could not quite decipher. Normally, I can relax and slip easily into a prayerful mode, but it was eluding me. In fact, all morning, something felt off. Even a co-worker before Mass asked me if I was OK because she said I, “looked out of sorts.” At the time, it struck me as odd.

As the service began, my phone vibrated on the pew beside me with the beats of someone calling. I ignored it because I was in church. It stopped, but began immediately anew. I looked down and saw my daughter’s name on the screen, and I knew …

Since the last few days of July, Madelyn, my daughter, had been fighting an unknown illness. Bumps and lumps developed under her arms, and she complained of pain. She switched deodorant several times. She’d go without deodorant. She switched soap. She went to several different doctors. She was diagnosed and prescribed one thing after another over the coming weeks with varying diagnoses with little to no improvement.

As parents, John, my husband, and I felt helpless, especially once she returned to Bethany College, four hours away from home. I would find myself saying seemingly trite phrases such as, “Take care of yourself”; “Get some rest”; “Drink plenty of water”; and so forth. The only thing we could really do was listen when she called, offer our love and support, and encourage her to take action in whatever form she felt appropriate.

However, this past week, Maddie had called every day as her symptoms seemed to come to a head. She was frustrated, tired, and stressed. Nothing seemed to be working, and she felt like no one was listening to her. In her mind, she was seen as just another whiny, female college student seeking attention.

Finally, Maddie asked me to ask my health-care provider his opinion. She had been researching her symptoms, talking with a concerned professor, and was worried the bigger issue was being overlooked. All of her symptoms pointed to scary sounding words that mostly started with the letter L: lupus, leukemia, lymphoma and one random condition, called hidradenitis suppurativa.

Therefore, I reached out to Alan Maynard, the health care provider for John and me. He very generously and nearly instantly took time to look at the pictures and texts Maddie had sent my way. He told me to tell her to insist on blood work on her next visit to the doctor and possibly ask for an ultrasound. Then, the next day, out of the blue, Alan sent me another message advising that Maddie should ask about hidradenitis suppurativa.

When the phone buzzed the second time during church, I knew I had to answer it. I quickly stepped outside into the bright, clear sunshine. The blood work Madelyn had insisted upon at Alan’s urging revealed an elevated white blood cell count. A doctor from the local Med Express had just called her to say she needed to report to the ER immediately.

“But I am fine, Mom, really. Jill will take me.”

Oh boy. I looked up at the sky. Now what? She’s four hours away.

I slipped back into church and sat down by John, who also teaches at SJCS. “We need to go,” he said.

“You need to go be a mom,” said our principal, Carol Templeton.

“We’re a family. We got both of your classes,” stated Justina White, our assistant principal.

Without belaboring any more details, our minds raced from one thought to another during the time it took to quickly pack, gas up, and make the drive. Jill, one of Maddie’s roommates, sent me regular text updates when Maddie could not. With each one, John and I grew more worried: IV drip of antibiotics, several vials of blood drawn, and ultrasound on armpits…

Looking back, I know my story-writing mind went into hyper-drive from the moment I took the call, but when you’re a parent, your kid is your priority – even at college age. Still, I should have talked myself down. I mean, we did get through potty training, the middle school years, and numerous other illnesses, including a broken arm, right?

Barring a random issue showing up in her blood that is still being cultured as I write this, all tests indicate that Alan’s instincts were correct: hidradenitis suppurativa. And, while that is a lifetime condition for which there is no, per se, cure, it is NOT any of the L-words, and for that, I am grateful. It can hopefully be successfully managed, once infection and initial treatment have been completed, with a few lifestyle changes.

For the record, while I had secretly been wishing I could see my daughter for my upcoming birthday, but knew she was busy, I would have preferred to spend time with her under completely different conditions! Still, I feel it was a gift to have once more wrapped my arms around my beautiful daughter, listen to her banter, and see those green eyes dance as she chided us for making the drive up.

I was further blessed to interact with her friends who, thankfully, take good care of each other. Additionally, I am blessed with the love of a husband who said, “We need to go,” and the support of a school family who allowed that to happen. And, of course, I also felt blessed by the love, prayers, and support of family, friends, and loved ones.

P.S. Thank you Alan for listening to Maddie when she felt her complaints were falling on deaf ears! You rock!

P.P.S. Thank you Sandy Taylor, Amy Vanhorn, Jillian and Stu, Dr. Kitchens, Cathy and Stephanie as well as the staff of Hampton Inn Wheeling. We appreciate your extra efforts as well!

Stephanie Hill is a freelance writer and a teacher at St. Joseph Catholic School in Huntington. She is also a lifelong resident of Lawrence County. She can be reached at hill992@zoominternet.net. Or you can check out her website, stephsimply.com.

Source link

US FDA accepts Samsung Bioepis' application for Humira biosimilar

… anti-tumor necrosis factor monoclonal antibody that currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, …

Source link

Hidradenitis Suppurativa? Cat Food's Abscess, Carbuncle, Boil… Procedure

Meta-Seven: https://amzn.to/2lYd5eM Part One: https://youtu.be/hglIp4l3IKI Blemish Removal Tools: http://amzn.to/2nifAfv RESTMORE: …

Source link

Herpes Zoster Risk Among Patients With Hidradenitis Suppurativa








Participants with hidradenitis suppurativa who received immunosuppression had an increased risk of developing herpes zoster.
Participants with hidradenitis suppurativa who received immunosuppression had an increased risk of developing herpes zoster.



The risk for patients with hidradenitis suppurativa (HS) developing herpes zoster (HZ) infection is low, even with immuosuppression therapies, according to a study published in Journal of the American Academy of Dermatology.

A retrospective cohort analysis, approved by the Institutional Review Board of the Feinstein Institute for Medical Research, examined at 30,355 individuals from the Explorys database, active from 2012 to 2017. The goal was to determine the incidence of HZ in people diagnosed with HS. Researchers compared the risk of developing HZ in participants with and without exposure to immuosuppression therapy.  Immuosuppression therapies considered included adalimumab, infliximab, methotrexate, cyclosporine, azathioprine, or glucocorticoid.

In individuals who did not receive immuosuppression therapy, the incidence of HZ was 0.42% in patients with HS and 0.38% in patients without HS. In individuals exposed to immuosuppression therapy, the incidence of HZ was 1.27% in patients with HS and 1.03% in patients without HS.

The study showed that immuosuppression therapies increased the incidence of HZ in patients with HS, but the risk was still low—below 2%. “While the need for vaccination should be assessed individually for patients,” researchers concluded, “those with HS generally may not require HZ vaccination, even with immunomodulation, prior to the age of 50 years.”

Disclosures: This study was funded in part by an education grant from AbbVie. An author declares affiliation AbbVie and other drug companies. Please see reference for a complete list of authors’ disclosures.

Reference

Wertenteil S, Strunk A, Garg A. Incidence of herpes zoster among patients with hidradenitis suppurativa: a retrospective population-based cohort analysis. [published online August 6, 2018]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2018.07.045



Source link

XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa

AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) —  XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion.

John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.”

The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated with bermekimab: those who have had and failed prior anti-TNF therapy; and those with no prior anti-TNF treatment history. Bermekimab was previously evaluated for treatment of hidradenitis suppurativa in a double blind, placebo controlled study. In that study, 60% of treated patients achieved the primary efficacy endpoint, a positive HiSCR, versus only 10% of patients who had received placebo. Patients were treated with an intravenous formula of bermekimab. Based on feedback from key opinion leaders, XBiotech developed and is now evaluating a subcutaneous formulation in pre-filled syringes that can be conveniently administered.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.   

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management’s beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the “Risk Factors” section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

Source link